Mouse Studies Advance Search for New Class of Antidepressants
Partnership Awards $3 Million In Grants For Promising New Treatments In Alzheimer’s And Related Dementias
JHDD start-up Lorem Therapeutics gets funding from IP Group
JHDD start-up Dracen Pharmaceuticals receives $40.5 million to develop Glutamine Antagonists
Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.